TEGSEDI: Target The Source

A product campaign for healthcare professionals

Power. Independence. Confidence. Three unique benefits of TEGSEDI, a treatment for the polyneuropathy of hereditary ATTR amyloidosis. No other drug directly binds to mRNA to inhibit protein production. No other drug lets patients live their lives on their terms.

The campaign delivers sophisticated and compelling data to healthcare professionals while humanizing the data with incredible patient stories.